Ian Quirt

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Epoetin alfa in patients not on chemotherapy - Canadian data
    Ian Quirt
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Semin Oncol 29:75-80. 2002
  2. ncbi request reprint Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy
    I Quirt
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 19:4126-34. 2001
  3. ncbi request reprint Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group
    Ian Quirt
    Department of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada
    Invest New Drugs 20:431-7. 2002
  4. ncbi request reprint Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience
    Ian Quirt
    Princess Margaret Hospital, Toronto, Ontario, Canada MG5 ZM9
    Oncologist 11:73-82. 2006
  5. ncbi request reprint Temozolomide for the treatment of metastatic melanoma: a systematic review
    Ian Quirt
    Princess Margaret Hospital, Toronto, Canada
    Oncologist 12:1114-23. 2007
  6. ncbi request reprint Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia
    Keyvan Karkouti
    Toronto General Hospital, University Health Network, Department of Anesthesia, 3 Eaton North, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Can J Anaesth 53:11-9. 2006
  7. ncbi request reprint Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
    Shailendra Verma
    Division of Medical Oncology, Ottawa Hospital, Ontario, Canada
    Cancer 106:1431-42. 2006
  8. pmc Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)
    Linh T Nguyen
    Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, University Health Network, Toronto, Canada
    PLoS ONE 5:e13940. 2010
  9. ncbi request reprint CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium
    Kim Margolin
    Division of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Cancer 104:1045-8. 2005
  10. ncbi request reprint Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review
    Teresa Petrella
    Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Cancer Treat Rev 33:484-96. 2007

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Epoetin alfa in patients not on chemotherapy - Canadian data
    Ian Quirt
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Semin Oncol 29:75-80. 2002
    ..Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy...
  2. ncbi request reprint Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy
    I Quirt
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 19:4126-34. 2001
    ..To evaluate efficacy, safety, and quality of life (QOL) changes with epoetin alfa therapy for anemia in patients with nonmyeloid malignancies...
  3. ncbi request reprint Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group
    Ian Quirt
    Department of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada
    Invest New Drugs 20:431-7. 2002
    ....
  4. ncbi request reprint Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience
    Ian Quirt
    Princess Margaret Hospital, Toronto, Ontario, Canada MG5 ZM9
    Oncologist 11:73-82. 2006
    ....
  5. ncbi request reprint Temozolomide for the treatment of metastatic melanoma: a systematic review
    Ian Quirt
    Princess Margaret Hospital, Toronto, Canada
    Oncologist 12:1114-23. 2007
    ..This systematic review examines the role of temozolomide in patients with metastatic melanoma. Outcomes of interest include response rate, progression-free survival, overall survival, quality of life, and adverse effects...
  6. ncbi request reprint Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia
    Keyvan Karkouti
    Toronto General Hospital, University Health Network, Department of Anesthesia, 3 Eaton North, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Can J Anaesth 53:11-9. 2006
    ..To determine if early recovery from severe post-operative anemia is accelerated by iv iron therapy alone or in combination with recombinant erythropoietin (EPO)...
  7. ncbi request reprint Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
    Shailendra Verma
    Division of Medical Oncology, Ottawa Hospital, Ontario, Canada
    Cancer 106:1431-42. 2006
    ..Until the results of ongoing trials are available, the authors could not state with confidence whether such therapy benefits patients with microscopically detected, sentinel lymph node-positive disease...
  8. pmc Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)
    Linh T Nguyen
    Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, University Health Network, Toronto, Canada
    PLoS ONE 5:e13940. 2010
    ..These protocols still have room for improvement and furthermore are currently only performed at a limited number of institutions. The goal of this work was to develop TILs as a therapeutic product at our institution...
  9. ncbi request reprint CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium
    Kim Margolin
    Division of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Cancer 104:1045-8. 2005
    ..CCI-779 is not immunosuppressive when administered on an intermittent schedule, and its toxicity is modest, consisting of nausea, diarrhea, hypertriglyceridemia, thrombocytopenia, asthenia, and follicular dermatitis...
  10. ncbi request reprint Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review
    Teresa Petrella
    Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Cancer Treat Rev 33:484-96. 2007
    ..Outcomes of interest include objective and complete response rates, duration of response, toxicity and quality of life...
  11. ncbi request reprint Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Susan Burdette-Radoux
    McGill University, Montreal, Quebec, Canada
    Invest New Drugs 22:315-22. 2004
    ..To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system...